Stock MXCT MAXCYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights MaxCyte, Inc.

Equities

MXCT

US57777K1060

Delayed London S.E.
Other stock markets
 11:04:34 16/05/2024 BST 		5-day change 1st Jan Change
365 GBX -1.35% Intraday chart for MaxCyte, Inc. 0.00% +3.55%
05-08 MaxCyte Shares Rise Sharply After Q1 Results Beat MT
05-08 MaxCyte shares rise amid double-digit revenue increase AN

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MaxCyte Shares Rise Sharply After Q1 Results Beat
MT
MaxCyte shares rise amid double-digit revenue increase
AN
Earnings Flash (MXCT.L) MAXCYTE Posts Q1 Revenue $11.3M
MT
Earnings Flash (MXCT.L) MAXCYTE Reports Q1 Loss $-0.09
MT
MaxCyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (MXCT) MAXCYTE Reports Q1 Revenue $11.3M, vs. Street Est of $7.5M
MT
Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024
CI
MaxCyte inks deal with Be Bio; Orcadian firms farmout
AN
MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines
CI
MaxCyte loss widens in 2023 as core revenue declines 25%
AN
MaxCyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Earnings Flash (MXCT) MAXCYTE Reports Q4 Revenue $15.7M, vs. Street Est of $15.1M
MT
MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024
CI
EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit
AN
MaxCyte Reaffirms Fiscal 2023 Revenue Guidance
MT
MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024
CI
MaxCyte, Wugen Enter Platform License Deal
MT
MaxCyte signs licencing deal with cell therapy company Wugen
AN
MaxCyte, Inc. and Wugen, Inc. Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-The-Shelf Cell Therapies for Cancers
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MXCT Stock
  4. News MaxCyte, Inc.
  5. Highlights